Latest Conference Articles

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.

Updated phase 3 progression-free survival and overall survival data demonstrated clinical benefits in efficacy and tolerability of oral paclitaxel and encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.

Under the 340B Prime Vendor Program, the Prime Vendor has several functions that it carries out to support stakeholders in operating and navigate the field so that they can effectively achieve lower 340B drug pricing for those who need it most.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Wearable technology and apps that monitor health and wellness have exploded in popularity and sophistication in recent years.

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.

Delirium is a common syndrome experienced by patients with COVID-19 while being treated in the ICU, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Monitoring outpatient prescribing patterns has been a major challenge for the Lifespan health system in Rhode Island, since it has over 1.5 million electronic prescriptions written annually.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.

There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Inhalation therapy is reliant upon correct inhaler technique to allow for optimal deposition of medication.

The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.

As the number of patients hospitalized with COVID-19 has surged, hospitals have been faced with the challenge of converting various spaces into ICUs and COVID-19 units.

The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

According to investigators, most medications should be stored at room temperature, between 68 and 77 degrees Fahrenheit.

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.

Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.

The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.

Session at at the San Antonio Breast Cancer Symposium featured several abstract presentations on disparities in health care access in breast cancer, including research on the necessity of avoiding a one-size-fits-all approach to medicine.

The COVID-19 Pandemic has compounded the opioid crisis.

Until COVID-19 vaccines are widely available, Anthony Fauci, MD, said the importance of public health measures cannot be understated.

Specifically, in rural settings, growing primary care provider shortages impact patient access to care.